Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 12 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 66.7%High 4 · 33.3%

Febuxostat 80 mg/day vs placebo

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Serious adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Serious adverse events · people with chronic gout

Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Serious adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review

Febuxostat 80 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 40 mg/day vs placebo

Withdrawals due to adverse events · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review